Cathy Eng

Het OligoPanc-project: expertconsensus over oligometastatisch pancreascarcinoom

NCI9673 (Part B): ETCTN Gerandomiseerde Fase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastat...

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-...

Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.

Health-related quality of life associated with fruquintinib in patiënten met metastatic colorectal cancer: Results fr...

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline.

Fruquintinib versus placebo bij refractair gemetastaseerd CRC: FRESCO-2 fase III

Gemetastaseerd colorectaal carcinoom: ASCO 2022 richtlijn

Cisplatine-5FU bij anaalcarcinoom: IRCI multicentrische fase II

Atezolizumab met of zonder cobimetinib versus regorafenib bij eerder behandeld gemetastaseerd CRC: IMblaze370